Pierre Bories

9PUBLICATIONS
54CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 18, 2025
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

B Ferment, J Lambert, D Caillot

|Sep 06, 2023
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

Jean Lemoine, Emmanuel Bachy, Guillaume Cartron

|Nov 01, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.

Alban Canali, Inès Vergnolle, Sarah Bertoli

|Oct 23, 2021
Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations.

Marie Sabatier, Emeline Boet, Sonia Zaghdoudi

|Oct 01, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.

Pierre Bories, Naïs Prade, Stéphanie Lagarde

Pageof 2

Frequent Collaborators

3 joint publications

Benoît Ferment

3 joint publications

Xavier Leleu

3 joint publications

Aurore Perrot

3 joint publications

Jill Corre